Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
THTX Stock Summary
Top 10 Correlated ETFs
In the News
Why Is Theratechnologies (THTX) Stock Down 22% Today?
Theratechnologies (NASDAQ: THTX ) stock is dropping on Thursday after the biopharmaceutical company announced a proposed public share offering. Theratechnologies is selling 12.5 million shares of THTX stock at a price of $1 per share.
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
MONTREAL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Paul Lévesque, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Fitzgerald Global Healthcare Conference 2023 being held September 26-28 in New York City.
Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
MONTREAL, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third quarter ended August 31, 2023, on Tuesday, September 26 at 8:30 a.m. EDT.
Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MONTREAL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Lévesque, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, to be held virtually and in person on September 11-13, 2023, in New York City at the Lotte New York Palace Hotel.
Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter ended May 31, 2023, on Wednesday, July 12 at 8:30 a.m. EDT.
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug conjugate (PDC) candidate, sudocetaxel zendusortide (formerly TH1902), in patients with advanced solid tumors. In a June 3 poster session at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, researchers will present early results from Part 1 (dose escalation) and Part 2 (dose expansion) of the multicenter, open-label trial of sudocetaxel zendusortide, in which 36% of heavily pretreated participants experienced a clinical benefit, including two patients with partial responses (PR) and seven achieving prolonged stable disease (SD).
Theratechnologies to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Montreal, Quebec--(Newsfile Corp. - April 18, 2023) - Theratechnologies (NASDAQ: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre. Dates: Tuesday April 25, 2023-Wednesday April 26, 2023 Time: 8:30 AM-4:30 PM ET Location: Metro Toronto Convention Centre, North Building 255 Front St W Toronto, Ontario M5V 2W6 Paul Levesque will be speaking at 11:30 ET on April 25th.
Theratechnologies stock price continues higher on company guidance
Theratechnologies (TSX:TH) Inc shares continued to advance Friday, up 12% to $1.29 following a 10% gain on Thursday, after the biopharmaceutical company announced that it expects its fiscal year 2023 revenue to be in the range of between $90 million and $95 million, representing commercial portfolio growth of between 13% and 19% over the past year. Theratechnologies (TSX:TH) also reported that its first quarter 2023 consolidated revenue rose 7.3% year-over-year to US$19,908,000, as sales of EGRIFTA SV reached US$12,711,000 and Trogarzo sales increased 5% to US$7,197,000 during the period.
Theratechnologies Inc. (THTX) Q1 2023 Earnings Call Transcript
Theratechnologies Inc. (NASDAQ:THTX ) Q1 2023 Earnings Conference Call April 12, 2023 8:30 AM ET Company Participants Elif McDonald - Head of Investor Relations Paul Levesque - President and Chief Executive Officer John Leasure - Global Commercial Officer Philippe Dubuc - Chief Financial Officer Christian Marsolais - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Justin Walsh - JonesTrading Edward Nash - Canaccord Genuity Endri Leno - National Bank Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies First Quarter Fiscal Year 2023 Earnings Call.
Theratechnologies shares up as first quarter revenues rise
Theratechnologies (TSX:TH) has reported first-quarter financial results with consolidated revenue growing by 7% to US$19.9mln. The Montreal-headquartered biopharmaceutical firm told investors that the performance was supported by a 9% growth in revenue from the EGRIFTA SV product along with 5% growth for Trogarzo which are both used by patients with HIV.
THTX Financial details
THTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-11-30
|Revenue per share||2.38||3.29||3.43||3.02||3.36|
|Net income per share||-0.25||-0.65||-1.18||-1.37||-1.98|
|Operating cash flow per share||0||-0.18||-0.7||-0.63||-0.62|
|Free cash flow per share||0||-0.36||-0.71||-0.63||-0.66|
|Cash per share||2.56||2.11||1.08||1.75||1.39|
|Book value per share||1.15||1.29||0.17||0.77||-0.95|
|Tangible book value per share||0.15||-0.77||-1.49||-0.26||-1.58|
|Share holders equity per share||1.15||1.29||0.17||0.77||-0.95|
|Interest debt per share||2.49||3.97||3.16||2.7||3.07|
|Price to sales ratio||10.35||3.85||2.68||4.36||2.53|
|EV to sales||9.48||4.19||3.33||4.89||3.07|
|Enterprise value over EBITDA||640.97||6.63K||-23.94||-20.9||-9.05|
|EV to operating cash flow||4.66K||-78.2||-16.21||-23.56||-16.73|
|EV to free cash flow||6.4K||-37.81||-16.17||-23.29||-15.68|
|Free cash flow yield||0||-0.03||-0.08||-0.05||-0.08|
|Debt to equity||2.25||2.87||17.18||3.2||-2.96|
|Debt to assets||0.44||0.61||0.55||0.48||0.72|
|Net debt to EBITDA||-58.29||552||-4.65||-2.23||-1.58|
|Sales general and administrative to revenue||0.13||0.13||0.19||0.21||0.22|
|Research and developement to revenue||0.18||0.17||0.27||0.4||0.46|
|Intangibles to total assets||0.29||0.34||0.32||0.2||0.16|
|Capex to operating cash flow||-0.27||1.07||0||0.01||0.07|
|Capex to revenue||0||-0.06||0||0||-0.01|
|Capex to depreciation||-0.01||-0.48||0||-0.02||-0.08|
|Stock based compensation to revenue||0.02||0.02||0.02||0.03||0.05|
|Return on tangible assets||-0.06||-0.16||-0.33||-0.33||-0.6|
|Tangible asset value||2.8M||-14.85M||-28.63M||-6.07M||-37.58M|
|Net current asset value||-2.5M||-16.54M||-32.11M||-9.54M||-42.46M|
|Days sales outstanding||0||58.41||72.86||57.13||56.28|
|Days payables outstanding||302.3||183.45||237.57||243.64||178.98|
|Days of inventory on hand||215.02||292.95||341.16||457.29||273.45|
|Capex per share||0||-0.19||0||-0.01||-0.04|
Quarterly Fundamentals Overview
Last date of statement is 2023-08-31 for Q3
|Revenue per share||0.88||0.9||0.82||0.73||0.86|
|Net income per share||-0.32||-0.33||-0.43||-0.41||-0.03|
|Operating cash flow per share||-0.05||-0.34||-0.14||-0.15||0.22|
|Free cash flow per share||-0.08||-0.35||-0.15||-0.15||0.22|
|Cash per share||1.53||1.38||1.2||1.05||0.95|
|Book value per share||-0.76||-0.94||-1.34||-1.72||-1.72|
|Tangible book value per share||-0.76||-1.57||-1.34||-1.72||-1.72|
|Share holders equity per share||-0.76||-0.94||-1.34||-1.72||-1.72|
|Interest debt per share||2.86||2.88||2.82||2.86||2.52|
|Price to sales ratio||9.87||9.51||4.62||5.24||1.11|
|EV to sales||11.94||11.51||6.93||8.07||3.19|
|Enterprise value over EBITDA||-53.93||-53.53||-32.37||-20.81||61.35|
|EV to operating cash flow||-207.78||-29.91||-41.31||-39.78||12.48|
|EV to free cash flow||-137.22||-29.83||-38.73||-38.89||12.52|
|Free cash flow yield||-0.01||-0.04||-0.04||-0.04||0.23|
|Debt to equity||-3.68||-2.96||-2.04||-1.61||-1.4|
|Debt to assets||0.69||0.72||0.83||0.97||1.03|
|Net debt to EBITDA||-9.34||-9.3||-10.79||-7.3||39.92|
|Sales general and administrative to revenue||0.2||0.18||0.22||0.21||0.18|
|Research and developement to revenue||0.4||0.44||0.47||0.59||0.26|
|Intangibles to total assets||0.13||0.16||0.18||0.2||0.23|
|Capex to operating cash flow||0.51||0||0.07||0.02||0|
|Capex to revenue||-0.03||0||-0.01||0||0|
|Capex to depreciation||-0.72||-0.02||-0.24||-0.09||-0.02|
|Stock based compensation to revenue||0.04||0.04||0.03||0.04||0.02|
|Return on tangible assets||-0.09||-0.1||-0.16||-0.18||-0.02|
|Tangible asset value||-30.91M||-37.58M||-46.58M||-55.06M||-54.56M|
|Net current asset value||-36.04M||-42.46M||-50.62M||-59.14M||-57.83M|
|Days sales outstanding||49.86||51.86||46.94||69.76||39.34|
|Days payables outstanding||698.57||196.27||653.63||616.1||551.87|
|Days of inventory on hand||393.55||299.87||289.77||167.97||121.82|
|Capex per share||-0.03||0||-0.01||0||0|
THTX Frequently Asked Questions
What is Theratechnologies Inc. stock symbol ?
Theratechnologies Inc. is a CA stock , located in Montreal of Qc and trading under the symbol THTX
What is Theratechnologies Inc. stock quote today ?
Theratechnologies Inc. stock price is $1.6001 today.
Is Theratechnologies Inc. stock public?
Yes, Theratechnologies Inc. is a publicly traded company.